Shire wins FDA approval to make Gammagard Liquid at new U.S. plant, ramps up hiring

Shire is being bought out by Takeda. (Shire)

It took longer than expected, but the FDA has approved the first product to be manufactured at Shire's new $1.2 billion plasma plant in the U.S.

The Dublin, Ireland-based drugmaker said Thursday that the FDA has approved its Gammagard Liquid, a replacement therapy for primary humoral immunodeficiency (PI), to be manufactured at the plant in Covington, Georgia.

Commercial production began in January, and Shire expects to be distributing the injected therapy soon now that it has won approval for the facility. It also is ramping up hiring for the facility where 900 employees already work. Shire says the new facility will add 30% capacity to Shire's internal plasma manufacturing network once it is fully operational.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“The increased manufacturing capacity from the site will support Shire's growing Immunology franchise and further strengthens our ability to deliver complex therapies for patients around the world living with a range of rare and immune-mediated conditions," Matt Walker, head of technical operations for Shire.

RELATED: Takeda to vault into Big Pharma with $62B Shire buyout—and megamerger cuts are on the way

Shire, which has agreed to a $62 billion buyout by Japan’s Takeda, picked up the plant and Gammagard Liquid in its $32 billion buyout of Baxalta in 2016. Shire had first said in January 2017 that the 1-million-square-foot facility plant was ready for commercial production and that it hoped to soon be producing Gammagard Liquid there.

Shire expects to make a second submission to the FDA this year for development of its albumin therapy at the Covington facility. Shire's albumin therapy is primarily used as plasma-volume replacement therapy in immune disorders, trauma and other critical conditions, it said.

Sales of Shire's immunoglobulin portfolio grew 18% last year and in the first quarter of 2018 was up 12%, driven by sales of subcutaneous products.

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.